(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
12 February 2015 (12.02.2015)

WIPO | PCT

(10) International Publication Number
WO 2015/018806 A1

(51) International Patent Classification:
A61K 39/02 (2006.01) *A61K 39/00* (2006.01)
A61K 39/155 (2006.01) *A61K 39/10* (2006.01)

(21) International Application Number:
PCT/EP2014/066756

(22) International Filing Date:
4 August 2014 (04.08.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
1313990.2 5 August 2013 (05.08.2013) GB
1401883.2 4 February 2014 (04.02.2014) GB

(71) Applicant: **GLAXOSMITHKLINE BIOLOGICALS S.A.** [BE/BE]; rue de l'Institut 89, B-1330 Rixensart (BE).

(72) Inventors: **STEFF, Ann-Muriel**; ID Biomedical Corporation of Quebec, 525 Cartier Boulevard West, Laval, Québec H7V 3S8 (CA). **TEMMERMAN, Stéphane T.**; GlaxoSmithKline Biologicals s.a., rue de l'Institut 89, B-1330 Rixensart (BE). **TOUSSAINT, Jean-François**; GlaxoSmithKline Biologicals s.a., rue de l'Institut 89, B-1330 Rixensart (BE).

(74) Agent: **WHITAKER, Duncan Andrew**; GlaxoSmithKline, Global Patents (CN925.1), 980 Great West Road, Brentford Middlesex TW8 9GS (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: COMBINATION IMMUNOGENIC COMPOSITIONS

(57) Abstract: Combination immunogenic compositions capable of eliciting protection against both RSV and B. pertussis infection and disease are disclosed. More specifically, this disclosure concerns such compositions which comprise a recombinant F protein analog of RSV, together with B. pertussis acellular (Pa) or whole cell (Pw) antigens and the use of the same, particularly in the context of neonatal and maternal immunization. Also disclosed are vaccine regimens, methods, as well as uses, and kits, of immunogenic compositions for protecting infants against disease caused by RSV and B. pertussis by maternal immunization.

WO 2015/018806 A1